SMS Lifesciences India Reports Strong Growth Amid Mixed Long-Term Performance Indicators

SMS Lifesciences India, a microcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an evaluation adjustment that reflects notable changes in its financial metrics. The company's performance for the quarter ending September 2025 has shown a positive trajectory, with key indicators such as Profit Before Tax less Other Income (PBT LESS OI) reaching Rs 8.07 crore, marking a significant growth rate of 203.38%. Additionally, the Debt-Equity Ratio stands at a low 0.34 times, indicating a strong balance sheet position.
The Operating Profit to Interest ratio has also reached a high of 8.38 times, while the Profit Before Depreciation, Interest, and Tax (PBDIT) is reported at Rs 13.58 crore. Furthermore, the company has achieved a Profit After Tax (PAT) of Rs 6.10 crore, reflecting a growth of 30.6%. Earnings Per Share (EPS) has reached Rs 20.20, showcasing the company's ability to generate shareholder value.

Despite these positive developments, the nine-month PAT has shown a decline of 24.70%, indicating some challenges in the longer-term performance metrics. Overall, SMS Lifesciences India has demonstrated a market-beating performance over various time frames, including a 19.22% return over the past year.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.